TTY Biopharm Co (ROCO:4105) Total Receivables: NT$1,385 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4105 TTY Biopharm Co Ltd ROCO:4105
83 GF Score
Price NT$79.10
GF Value NT$87.56
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is TTY Biopharm Co Total Receivables?

TTY Biopharm Co ROCO:4105 +1.28% 83 Total Receivables is NT$1,385 Mil as of Mar. 2026. GuruFocus rates ROCO:4105 with a GF Score™ of 83/100 and a GF Value™ of NT$87.56 (Modestly Undervalued). The stock has 1 warning sign investors should review.

TTY Biopharm Co's Total Receivables for the quarter that ended in Mar. 2026 was NT$1,385 Mil.

TTY Biopharm Co Total Receivables Related Terms

TTY Biopharm Co Total Receivables Historical Data

* Premium members only.

The historical data trend for TTY Biopharm Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TTY Biopharm Co Total Receivables Chart

TTY Biopharm Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,151.38 1,256.82 1,372.54 1,376.85 1,554.34

TTY Biopharm Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,328.46 1,453.18 1,736.03 1,554.34 1,385.05
ROCO:4105
83GF Score
TTY Biopharm Co Ltd ROCO:4105
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TTY Biopharm Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of NT$1,385 Mil mean?
TTY Biopharm Co (ROCO:4105) has a Total Receivables of NT$1,385 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on TTY Biopharm Co and its competitors.
Is TTY Biopharm Co's Total Receivables too high?
TTY Biopharm Co's current Total Receivables is NT$1,385 Mil. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Total Receivables compare to ZTS and UTHR?
TTY Biopharm Co's Total Receivables of NT$1,385 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on TTY Biopharm Co and its competitors. TTY Biopharm Co's current Total Receivables is NT$1,385 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.56, compared to a current price of NT$79.10 — trading 9.7% below its estimated fair value. The current Total Receivables is NT$1,385 Mil. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Total Receivables is NT$1,385 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?

Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued. The current stock price of NT$79.10 is trading 9.7% below its estimated GF Value™ of NT$87.56. GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.

Key valuation signals for ROCO:4105:

  • Total Receivables: NT$1,385 Mil
  • GF Value™: NT$87.56 vs. price of NT$79.10 (9.7% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TTY Biopharm Co Business Description

Address No. 3-1, Park Street, 3rd Floor, Nangang District, Taipei, TWN, 11503
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score

Get the complete analysis for ROCO:4105

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$79.10
Price
NT$87.56
GF Value